Real-world evidence of fruquintinib (Fruq) efficacy after regorafenib (Rego) and trifluridine–tipiracil (TAS-102) in refractory metastatic colorectal cancer (mCRC).
Oluseyi Abidoye(Mayo Clinic), Daniel H. Ahn(Mayo Clinic Hospital), Mohamad Bassam Sonbol(WinnMed), Fang‐Shu Ou(Mayo Clinic), Tanios Bekaii‐Saab(WinnMed), Anina Peersen(Mayo Clinic), Christina Wu(WinnMed), Jennah Bauernfeind(Mayo Clinic Hospital)
Cited by 0
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
|Nature Reviews Clinical Oncology|2020|365